Status:
COMPLETED
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
Lead Sponsor:
Qlaris Bio, Inc.
Conditions:
Normal Tension Glaucoma (NTG)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A randomized active-controlled multi-site double-masked 28 day study to evaluate the safety and tolerability of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjec...
Eligibility Criteria
Inclusion
- Visual acuity +1.0 logMAR or better
- Willing to give informed consent
- Ability to washout from current intraocular pressure lowering medications -
Exclusion
- All secondary glaucomas
- Previous glaucoma intraocular or laser surgery (selective laser trabeculoplasty permitted when done 18 months or longer from Screening)
- Refractive surgery
- Ocular infection or inflammation
Key Trial Info
Start Date :
September 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 26 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04857827
Start Date
September 15 2021
End Date
August 26 2022
Last Update
January 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vance Thompson Vision
Sioux Falls, South Dakota, United States, 57108